Background: Tuberculosis (TB) remains one of the major global health threats leading to morbidity and mortality. The present study was conducted to compare levofloxacin or moxifloxacin for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-TB). Materials & Methods: The present study comprised of 112 patients of multidrug-resistant tuberculosis (MDR-TB) of both genders. Patients were divided into 2 groups of 56 each. Group I patients were given 750 mg/d levofloxacin and group II patients were given 400 mg/d moxifloxacin. Treatment responses were categorized into treatment success (cured and treatment completed) or adverse treatment outcome (death, failure, and relapsed). Results: Group I patients were given 750 mg/d levofloxacin and group II patients were given 400 mg/d moxifloxacin. Duration of treatment in group I was 516 days and in group II was 617 days, number of drugs used in both groups was 5, resistant drugs were 4 in both groups, adverse drug reactions were eye toxicity seen in 6 in group I and 3 in group II, hepatotoxicity 4 in group I and 2 in group II, Hematologic abnormalities were 2 in group I and 1 in group II, dermatological abnormalities were 3 in group I and allergic reactions were 2 in group I and 1 in group II. 42 patients in group I and 38 in group II were cured and 14 in group I and 18 in group II had complete treatment, treatment failure was seen in 3 in group I and 4 in group II and death were seen in 2 in group I and 3 in group II. The difference was significant (P< 0.05). Conclusion: Authors found that patients on levofloxacin showed better treatment outcome as compared to moxifloxacin groups. Key words: Levofloxacin, Moxifloxacin, Tuberculosis